Metastatic Uveal Melanoma Clinical Trials

10 recruiting

Metastatic Uveal Melanoma Trials at a Glance

10 actively recruiting trials for metastatic uveal melanoma are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in New York, Philadelphia, and Los Angeles. Lead sponsors running metastatic uveal melanoma studies include H. Lee Moffitt Cancer Center and Research Institute, M.D. Anderson Cancer Center, and IDEAYA Biosciences.

Browse metastatic uveal melanoma trials by phase

Treatments under study

About Metastatic Uveal Melanoma Clinical Trials

Looking for clinical trials for Metastatic Uveal Melanoma? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Uveal Melanoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Uveal Melanoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 1

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Lung Non-Small Cell CarcinomaMetastatic Melanoma+7 more
M.D. Anderson Cancer Center75 enrolled1 locationNCT03025256
Recruiting
Phase 2Phase 3

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma
Replimune, Inc.280 enrolled33 locationsNCT06581406
Recruiting
Phase 2

Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute18 enrolled1 locationNCT07276386
Recruiting
Phase 2

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

Metastatic Uveal MelanomaMetastatic Uveal Melanoma in the Liver
University of Miami30 enrolled1 locationNCT06627244
Recruiting
Phase 1

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

MelanomaMetastatic MelanomaUveal Melanoma+1 more
Memorial Sloan Kettering Cancer Center30 enrolled2 locationsNCT05607095
Recruiting
Phase 1Phase 2

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Cutaneous MelanomaMetastatic Uveal Melanoma
IDEAYA Biosciences336 enrolled15 locationsNCT03947385
Recruiting
Phase 2

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute32 enrolled4 locationsNCT06121180
Recruiting
Phase 1Phase 2

Tebentafusp-tebn With LDT in Metastatic UM

Metastatic Uveal Melanoma
Thomas Jefferson University109 enrolled1 locationNCT06626516
Recruiting
Phase 1Phase 2

Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma

Metastatic Uveal MelanomaUveal Melanoma, MetastaticUveal Melanoma, Recurrent+2 more
Novelwise Pharmaceutical Corporation36 enrolled3 locationsNCT07136181
Recruiting
Phase 1Phase 2

Adding IL-2 to Tebentafusp to Eradicate Cancer Progression

Uveal MelanomaMetastatic Uveal MelanomaMetastatic Uveal Melanoma in the Liver
St Vincent's Hospital, Sydney8 enrolled2 locationsNCT07063875